The Association for Accessible Medicines wants Congress to focus on six areas to protect against practices that generic drug makers say delay generic and biosimilar competition. Their proposals range from preserving procompetitive settlement agreements for patents, to prohibiting rebate traps meant to delay coverage and access to lower-costing alternatives to putting an end to the spread of misinformation about generic and biosimilar products. AAM submitted the recommendations at a July 13 Senate Judiciary subcommittee hearing on boosting pharmaceutical competition through...